Last reviewed · How we verify
DT
DT is a diphtheria and tetanus toxoid vaccine that stimulates the immune system to produce antibodies against diphtheria and tetanus toxins.
DT is a diphtheria and tetanus toxoid vaccine that stimulates the immune system to produce antibodies against diphtheria and tetanus toxins. Used for Active immunization against diphtheria and tetanus in infants and children.
At a glance
| Generic name | DT |
|---|---|
| Also known as | Pegylated liposomal doxorubicin and Docetaxel |
| Sponsor | Hoffmann-La Roche |
| Drug class | Toxoid vaccine |
| Target | Diphtheria toxin and tetanus toxin |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease Prevention |
| Phase | FDA-approved |
Mechanism of action
DT contains inactivated diphtheria and tetanus toxoids (modified bacterial toxins) that trigger adaptive immune responses without causing disease. The body produces specific antibodies and cellular immunity against these toxins, providing protection against infection by Corynebacterium diphtheriae and Clostridium tetani. This is a toxoid-based vaccine approach used primarily in pediatric immunization schedules.
Approved indications
- Active immunization against diphtheria and tetanus in infants and children
Common side effects
- Local injection site reactions (pain, redness, swelling)
- Fever
- Irritability or fussiness
- Drowsiness
Key clinical trials
- Effects of Dual Task-Oriented Circuit Training on Walking Recovery in Sub-acute Stroke (NA)
- Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse (PHASE2)
- Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma (PHASE1)
- Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma (PHASE1)
- Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC) (PHASE1, PHASE2)
- Nucleoside Therapy in Patients With Telomere Biology Disorders (PHASE1)
- REVEAL Study - Diagnostic Testing for PTSD Using the Senseye Diagnostic Tool (PHASE3)
- A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |